Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent

Jasper Therapeutics, Inc. made a significant achievement with positive early data on use of briquilimab as a conditioning agent for patients with sickle cell disease (SCD) and beta-thalassemia undergoing allogeneic stem cell transplant, especially after another company seeking to develop an alternative to the chemotherapy drugs traditionally used in the space, Magenta Therapeutics, Inc., announced a setback in its own program.

Jasper said on 3 January that the first three participants in an investigator-initiated Phase I/II study of briquilimab successfully engrafted with neutrophil engraftment within 12-16 days, with the first two patients with peripheral blood chimerism achieving 100% donor myeloid chimerism at 60 days after transplant